-2%
- Gefitinib inhibits the ATP-binding site of the EGFR tyrosine kinase, preventing the activation of the Ras signal transduction cascade.
- This inhibition suppresses malignant cell growth and proliferation.
- EGFR is commonly overexpressed in cancers like lung and breast cancer, driving uncontrolled cell growth.
- Gefinix 250 is used for the treatment of non-small cell lung cancer (NSCLC):
- Specifically in patients with metastatic cancer.
- Those with abnormal epidermal growth factor receptor (EGFR) genes.
- Patients who have not received prior cancer treatment.
- Can be taken with or without food, ideally at the same time daily, and continued as prescribed by a doctor.